• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Is Duloxetine Use During Pregnancy Linked to Adverse Outcomes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Duloxetine (Cymbalta) is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression, anxiety and pain disorders
  • Huybrechts et al. (BMJ, 2020) assessed the risk for adverse perinatal outcomes following prenatal exposure to duloxetine

METHODS:

  • Cohort study
    • Using a nationwide database
  • Participants
    • Pregnant women | Ages 18 to 55 their liveborn infants
  • Exposures
    • Duloxetine exposure during the etiologically relevant time window (e.g., first trimester more relevant for congenital anomalies, while late exposure may be more important for PPH or preterm birth)
    • No exposure to duloxetine
    • Exposure to selective serotonin reuptake inhibitors
    • Exposure to venlafaxine (Effexor) to compare individual effects of duloxetine vs another SNRI
    • Exposure to duloxetine before but not during pregnancy
  • Primary outcomes
    • Congenital malformations overall
    • Cardiac malformations
    • Preterm birth
    • Small for gestational age infant
    • Preeclampsia
    • Postpartum hemorrhage

RESULTS:

  • Source cohort size: 8,410,882 pregnant women
  • All baseline characteristics were well balanced for all exposure contrasts, following adjustment for measured potential confounders

Comparing duloxetine vs unexposed pregnancies

  • Overall congenital malformations
    • Adjusted relative risk (RR) 1.11 (95% CI, 0.93 to 1.33)
  • Cardiovascular malformations
    • aRR 1.29 (95% CI, 0.99 to 1.68) 
    • When analysis was performed using 2 dispensings of duloxetine in the first trimester adjusted risk estimates strengthened
  • Preterm birth
    • Early exposure; aRR 1.01 (95% CI, 0.92 to 1.10) for early exposure
    • Late exposure: aRR 1.19 (95% CI, 1.04 to 1.37)
  • SGA
    • Early exposure: aRR 1.14 (95% CI, 0.92 to 1.41)  
    • Late exposure: aRR 1.20 (95% CI, 0.83 to 1.72) 
  • Preeclampsia  
    • Early exposure: aaRR 1.12 (95% CI, 0.96 to 1.31)  
    • Late exposure: RR 1.04 (95% CI, 0.80 to 1.35) 
  • PPH
    • Late exposure: aRR 1.53 (95% CI, 1.08 to 2.18)

CONCLUSION:

  • Duloxetine is unlikely to be a major teratogen
  • There may be an increased risk for cardiovascular anomalies  
  • There was an increased risk for PPH | Duloxetine depletes platelet serotonin
  • The authors state that the

…potential small increases in risk of relatively uncommon outcomes that we observed must be weighed against the benefits of treating depression and pain during pregnancy for both the mother’s and the infant’s health, a trade-off that is likely to be different for each individual patient.

Learn More – Primary Sources:

Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst®

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Maternal Depression or Stress Affect Fetal Growth?
Do Antidepressants During Pregnancy Increase Autism Risk?
SSRI Exposure and MRI findings – More Research is Needed

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site